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Background: Small-cell lung carcinoma (SCLC) is a neuroendocrine tumor subtype and comprises approximately
15% of lung cancers. Because SCLC is still a disease with a poor prognosis and limited treatment options, there is
an urgent need to develop targeted molecular agents for this disease.
Methods: We screened 20 cell lines from a variety of pathological phenotypes established from different organs by
RT-PCR. Paraffin-embedded tissue from 252 primary tumors was examined for PTPRZ1 expression using
immunohistochemistry. shRNA mediated PTPRZ1 down-regulation was used to study impact on tyrosine
phosphorylation and in vivo tumor progression in SCLC cell lines.
Results: Here we show that PTPRZ1, a member of the protein tyrosine- phosphatase receptor (PTPR) family, is
highly expressed in SCLC cell lines and specifically exists in human neuroendocrine tumor (NET) tissues. We also
demonstrate that binding of the ligand of PTPRZ1, pleiotrophin (PTN), activates the PTN/PTPRZ1 signaling pathway
to induce tyrosine phosphorylation of calmodulin (CaM) in SCLC cells, suggesting that PTPRZ1 is a regulator of
tyrosine phosphorylation in SCLC cells. Furthermore, we found that PTPRZ1 actually has an important oncogenic
role in tumor progression in the murine xenograft model.
Conclusion: PTPRZ1 was highly expressed in human NET tissues and PTPRZ1 is an oncogenic tyrosine phosphatase
in SCLCs. These results imply that a new signaling pathway involving PTPRZ1 could be a feasible target for
treatment of NETs.
Keywords: Small cell lung carcinoma (SCLC), Protein tyrosine phosphatase (PTP), Protein tyrosine phosphatase
receptor Z1 (PTPRZ1), NETs (Neuroendocrine tumors), Pleiotrophin (PTN), Calmodulin (CaM)Background
Neuroendocrine tumors (NETs) that includes small cell
lung carcinomas (SCLC), large cell neuroendocrine car-
cinomas (LCNEC), pancreatic neuroendocrine tumors
(PanNET), medullary thyroid carcinomas (MTC), pheo-
chromocytomas, paragangliomas, and carcinoids [1-4].
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distribution, and reproduction in any mediumapproximately 15% of lung cancer cases, and basic and
clinical research efforts have translated little innovation
in the treatment of this disease over the past 30 years
[5]. Although SCLC appears to be effectively controlled
with first line chemotherapy because of its relative high
sensitivity to chemotherapy and radiotherapy, most
patients ultimately relapse and salvage chemotherapy is
considered [6]. To identify novel drug targets against
SCLC, a greater understanding of the pathology of SCLC
through molecular analysis is urgently needed.
Dissection of the signaling pathways that may be
involved in the regulation of SCLC growth, for example
via phosphorylation or dephosphorylation of critical pro-
teins, may shed light on new approaches for tumorentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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regulated by protein tyrosine-kinases (PTKs) and protein
tyrosine-phosphatases (PTPs) [7,8]. PTPs play an im-
portant role in the inhibition and control of growth as
tumor suppressors, since aberrant tyrosine phosphoryl-
ation is a characteristic feature of cancer cells [7-9]. In-
deed, PTPs expressed as cell surface receptors (PTPRs)
have been reported to be inactivated by genetic muta-
tions in human cancer [9,10]. On the other hand, there
is mounting evidence suggesting that several PTPRs also
have oncogenic function [9].
PTPRZ1, as a member of the PTPR family, is a single-
pass type I membrane protein with two cytoplasmic
tyrosine phosphatase domains (D1 and D2), an alpha-
carbonic anhydrase domain (CA), chondroitin sulfate
proteoglycans (CS-PGs) and a fibronectin type-III do-
main (FNIII) [11]. PTPRZ1 interacts with its ligand
pleiotrophin (PTN), which is a secreted growth factor
involved in angiogenesis and tumor growth [12,13].
Upon binding, PTN inactivates the phosphatase activity
of PTPRZ1, which leads to an increased tyrosine phos-
phorylation status of important signaling molecules such
as β-catenin, Fyn and RhoGAP [14-18]. With regard to
cancer, PTPRZ1 expression was dramatically induced by
genetic amplification caused by chronic oxidative stress
and hypoxic stress through HIF-2 alpha [14,19] and sev-
eral previous studies suggested that PTPRZ1 regulates
cancer cell growth and cell migration [18,20-24].
In this paper, we found that PTPRZ1 is highly
expressed in SCLC cell lines and specifically exists in
human NET tissues. We hypothesized that PTPRZ1
functions to regulate tyrosine phosphorylation in SCLC
cells and has an important role for SCLC tumor progres-
sion. To test this idea, we investigated the ability of
PTPRZ1 to regulate tyrosine phosphorylation and tumor
progression using SCLC cell lines.
Methods
Cell cultures
LN229 (glioblastoma, ATCC#CRL-2611), U87MG (glio-
blastoma/astrocytoma, ATCC#HTB-14), Hela (cervix
ADCA, ATCC#CCL-2), Caco2 (colorectal ADCA,
ATCC#HTB-37), DLD1 (colorectal ADCA, ATCC#CCL-
221), HCT116 (colorectal ADCA, ATCC#CCL-247),
SW480 (colorectal ADCA, ATCC#CCL-228), A549 (lung
ADCA, ATCC#CCL-185), LNCaP (prostate ADCA,
ATCC#CRL-1740), MCF7 (breast ADCA, ATCC#HTB-
22), A431 (squamous cell carcinoma, ATCC#CRL-1555),
NCI-H69 (SCLC, ATCC#HTB-119), NCI-H82 (SCLC,
ATCC#HTB-175), NCI-H345 (SCLC, ATCC#HTB-180),
NCI-H446 (SCLC, ATCC#HTB-171), NCI-H510A (SCLC,
ATCC#HTB-184), NCI-H1436 (SCLC, ATCC#CRL-5871),
and NCI-H1930 (SCLC, ATCC#CRL-5906) were originally
purchased from ATCC and stocked in our ResearchCenter. TE1 (esophagus squamous cell carcinoma), TE3
(esophagus squamous cell carcinoma), TE4 (esophagus
squamous cell carcinoma), TE5 (esophagus squamous cell
carcinoma), and TE10 (esophagus squamous cell carcin-
oma) were gifts from Dr. Sasaki (National Cancer Center
Research Institute). SBC-3 (SCLC, #JCRB0818) was
obtained from the JCRB and stocked in our Research Cen-
ter. All cell lines were cultured in cell culture dishes (BD
Biosciences) at 37°C and 5% carbon dioxide using RPMI
1640 (SIGMA), DMEM (SIGMA) supplemented with 10%
fetal bovine serum (FBS, Nichirei Bioscience), or HITES
Medium [25,26] supplemented with penicillin/strepto-
mycin (Invitrogen). For the PTN assay, 100 ng/ml of
recombinant human pleiotrophin/PTN (R&D Systems
#252-PL) was used.
Human cancer samples
Samples were obtained with informed consent from each
individual, and the study was approved by the Ethics
Committee of the National Cancer Center East Hospital.
During the period from January 1992 to December 2010,
a total of 252 patients who had primary tumors were
treated at the National Cancer Center Hospital East,
Chiba, Japan. All primary cancers with a pathologic diag-
nosis based on the classification schema of the WHO
classification were reviewed, with 105 cases as adenocar-
cinoma (ADC), 61 as squamous cell carcinoma (SQCC)
and 86 as neuroendocrine tumors (NETs). We used tis-
sue microarray (TMA) to measure PTPRZ1 expression
within lung tumors [27]. Each case in which more than
80% of the cancer cells reacted positively for an antibody
to PTPRZ1 was recorded as positive.
Antibodies
Antibodies used included anti-PTPRZ1 (SIGMA #015103)
[28], anti-Phosphotyrosine, clone 4 G10 (Millipore
#05-321), anti-Calmodulin (Santa Cruz sc-5537, Millipore
#05-173, abcam ab45689), anti-phospho-Calmodulin
(Santa Cruz Biotechnology sc-23760-R, Millipore
#09-295) and anti-β-tublin (Cell Signaling #2146).
Immunohistochemistry (IHC)
All immunohistochemical (IHC) analyses were per-
formed on paraffin-embedded tissues obtained from the
primary tumor in the surgical specimen. For all IHC
analyses the surgically resected specimens were fixed in
10% formalin and embedded in paraffin for routine
pathological examination. We prepared and used 5-μm-
thick paraffin sections cut from a paraffin block contain-
ing histological findings that were representative of the
tumor. The procedure for IHC was previously described
[27,28]. Antigen retrieval was performed in citrate buffer
solution (pH 6.0). Endogenous peroxidase was blocked
with 0.3% H2O2 in methanol for 15 min and all slides
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ation for 20 min and then cooled at room temperature
(RT). Slides were washed in PBS and after a 1 h incuba-
tion at RT with the primary antibodies, the slides were
incubated for 30 min with a labeled polymer EnVision
TM+, Peroxidase–conjugated anti-Mouse or Rabbit
(Dako, Tokyo, Japan). The chromogen used was 2% 3,
30-diaminobenzidine (DAB) in 50 mM Tris-buffer
(pH 7.6) containing 0.3% hydrogen.
RNA isolation and real-time RT–PCR
Cells were washed with PBS and total RNA from the cell
lines was isolated with TRIzol Reagent (Invitrogen).
Complementary DNA (cDNA) was synthesized using the
PrimeScriptW RT reagent Kit (TaKaRa, Japan). Real-time
RT–PCR was carried out with specific primers and a
Smart Cycler (Cepheid, Sunnyvale, CA, USA). Real-time
fluorescence monitoring of the PCR products was per-
formed with SYBR Green I fluorescent dye (TaKaRa).
The levels of expression of specific genes are reported as
ratios to the level of expression of GAPDH in the same
master reaction. Synthesized primers were purchased
from TaKaRa Bio with Primer Set ID given as PTPRZ1,
30 (HA082543). GAPDH was used for normalization as
control and the relative quantitation value compared to
the calibrator for that target is expressed as 2-(Ct-Cc).
Western blot
Western blotting was performed as described [29]. After
lentivirus infection with the vector for shLUC or
shPTPRZ1, total cell lysate was prepared from cells cultured
in complete medium. Primary antibodies were used at
1:1000 dilution and β-tubulin was used as loading control.
Expression of short hairpin RNA (shRNA)
Plasmid construction was carried out with Gateway sys-
tem (Invitrogen) according to the manufacturer’s instruc-
tions. Cloning vectors were pDNOR221 (Invitrogen) and
pENTR/U6 (Invitrogen). The lentiviruses were produced
using 293FT cells (Invitrogen) transfected with pCAG-
HIVgp, pCMV-VSV-G-RSV-Rev, and a lentivirus vector
based on CSII-CMV-RfA-IRES2-Venus (Dr. Miyoshi,
RIKEN BioResource Center) expressing shRNA with the
sequence described below. Transfection was achieved
using Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s instructions. Lentivirus-containing
medium was filtered through a 0.45 μm filter and used
for transduction of target cells. The sequences and plas-
mid names were; shLUC: GTGCGCTGCTGGTGCCAAC
(pGL3, firefly luciferase), shPTPRZ1_1: GCCTATAAATT-
GTGAGAGCTT (pHMA017), shPTPRZ1_2: GCTGCTT-
TAGATCCATTCATA (pHMA019), and shPTPRZ1_3:
GGATGGCAAACTGACTGAT (pHMA022).Flow cytometry
Cells were incubated with anti-PTPRZ1 antibody
(SIGMA) and excess antibody was removed by wash-
ing with PBS containing 2% FBS. Polyclonal goat anti-
rabbit immunoglobulin conjugated to Phycoerythrin (PE)
(Jackson) was added as a secondary antibody. The cells
were then washed with PBS and flow cytometric analysis
was performed using a FACSCalibur and FACSAria (BD
Biosciences).
Animal studies
All of experimental SCID mice were handled in accord-
ance with institutional guidelines established by the Ani-
mal Care Committee of the National Cancer Center East
Hospital. H69 and H1930 SCLC cells expressing shRNA
were injected into the subcutaneous tissue of SCID mice
(7–8 weeks of age, CLEA, Tokyo, Japan). Tumor volume
was calculated as the product of a scaling factor of 0.52
and the tumor length, width, and height were measured
every week. For IHC analysis, organs were obtained from
mice at 5 or 8 weeks after injection and fixed in 10%
formalin.
Statistical methods
Standard Student’s t-test was used to determine the sig-
nificance between non-targeting control and shPTPRZ1
experiments. Statistical correlation was carried out using
χ2test for independence (2 × 2 contingency table).
P < 0.05 was considered statistically significant.
Results
PTPRZ1 is highly expressed in SCLC cell lines
To assess mRNA expression of PTPRZ1 comprehen-
sively in human cancers, we screened 20 cell lines from
a variety of pathological phenotypes established from
different organs by RT-PCR. We observed that two
SCLC cell lines at the first screening, NCI-H69 (H69)
and NCI-H1930 (H1930), expressed PTPRZ1 mRNA at
significantly higher levels than other cell lines
(Figure 1A). To confirm the specificity of PTPRZ1 ex-
pression in SCLC cells, we measured PTPRZ1 protein
levels by Western blotting (Figure 1B). The human
PTPRZ1 gene encodes a core protein consisting of 2315
amino acids (NCBI Reference Sequence: NP_002842)
with a predicted molecular weight (M.W.) of 400 kDa,
[30]. Indeed, we detected a specific band of PTPRZ1
protein at approximately 400 kDa by WB, only within
SCLC cell lines expressing PTPRZ1 mRNA at high levels
(Figure 1B).
PTPRZ1 is specifically expressed in human NET tissues
To determine globally which human tumor tissues
expressed PTPRZ1, we analyzed immunohistochemical
(IHC) evaluations of a variety of tumors including 105
Figure 1 Gene expression of PTPRZ1 among the different cancer cell lines. Glial, adenocarcinoma (ADCA), squamous cell carcinoma (SQCC)
and neuroendocrine tumor (NET) cell lines were screened for PTPRZ1 mRNA levels (normalized to GAPDH), with standard deviation error bars
shown (A). PTPRZ1 was expressed in SCLC cell lines at protein level (B).
Figure 2 PTPRZ1 was expressed in human NETs. A–D, Representative microscopic images for PTPRZ1-negative SCLC (A), PTPRZ1-positive
SCLC (B), Thyroid Medullary carcinoma (TMC) (C) and Pancreatic endocrine tumor (PanNET) (D). Scale bars are 20 μm (Magnification X40). E, The
percentage of PTPRZ1 expression in human tumor tissues was measured in ADCA, SQCC, and NET pathological types including lung ADCA (LA),
breast ADCA (BA), gastric ADCA (GA), pancreatic ADCA (PA), colon ADCA (CA), Thyroid ADCA (TA), lung SQCC (LS), esophagous SQCC (ES),lung
NET (LN), thyroid NET (TN), pancreatic NET (PN), chromaffin-cell NET (CT), and gastrointestinal carcinoid (GC).
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cell carcinoma (SQCC) and 86 cases NET. In non-tumor
tissues, we specifically observed PTPRZ1 expression in
the neural cells and endocrine cells such as peripheral
nerves, pancreatic islets and adrenal chromaffin cells.
Representative IHC evaluations of PTPRZ1-positivity
(PTPRZ1+) with anti-PTPRZ1 antibody in a variety of
NETs are shown in Figure 2, for PTPRZ1-negative
(PTPRZ1-) SCLC (A), PTPRZ1+ SCLC (B), MTC (C),
and PanNET (D). PTPRZ1 was mainly localized in the
cell membrane as well as the cytosol. We found that
PTPRZ1 was detected at high frequency and intensity in
a variety of human NETs including 60% of SCLCs
(Figure 2E, Table 1). PTPRZ1 was expressed at much
higher levels in NETs (79%) than in ADCA (9%) and
SQCC (20%) (Figure 2E).
RNAi knockdown of PTPRZ1 in SCLC cell lines
To characterize further the function of PTPRZ1 in SCLC
cells, we employed a genetic approach to repress
PTPRZ1 expression using by RNA interference (RNAi).
For potential off-target shRNA effects, three different
sequences of shRNA directed against PTPRZ1 (shZ1#1,
#2 and #3) and a nontargeting shRNA (shLUC) were
constructed. While the introduction of the first con-
struct shZ1#1 in SCLC cells did not appear to down-
regulate PTPRZ1 mRNA levels as compared to control
shLUC when measured by quantitative RT-PCR, signifi-
cant reduction in mRNA expression of 75% using
shZ1#2 and 60% using shZ1#3 could be observed in the
expression of PTPRZ1 in the SCLC cell lines H69 andTable 1 The IHC analysis of PTPRZ1 expression in human
tumor tissues
Tumors PTPRZ1− PTPRZ1+ %
Adenocarcinoma (ADCA) 9
Lung ADCA 44 1 2
Breast ductal ADCA 8 2 20
Gastric ADCA 10 0 0
Pancreatic ductal ADCA 15 5 25
Colon ADCA 10 0 0
Thyroid papillary carcinoma 9 1 10
Squamous cell carcinoma (SQCC) 20
Lung SQCC 41 10 20
Esophagus SQCC 8 2 20
Neuroendocrine tumor (NET) 79
Lung NET 11 8 42
Medullary thyroid carcinoma 0 16 100
Pancreatic NET 5 26 84
Chromaffin cell tumor 0 10 100
Gastointestinal carcinoid 8 2 80H1930 (Figure 3A). WB analyses also revealed significant
decreases in PTPRZ1 protein expression upon introduc-
tion of shZ1#2 and #3, as compared to a control vector,
in H69 and H1930 under normal culture conditions
(Figure 3B). To measure cell surface PTPRZ1 levels in
shZ1-transduced SCLC cells, we used flow cytometry
(FACS). FACS analysis of shLUC-SCLC cells and shZ1-
SCLC cells also revealed significant reduction of
PTPRZ1 expression on SCLC cellular surface from 29%
to 6–7% in H69 cells and 37% to 9–12% in H1930 cells
(Figure 3C).
PTN induced calmodulin tyrosine phosphorylation in
SCLC cells
Although our findings demonstrated that PTPRZ1 was
specifically up-regulated in SCLC cells, no studies to
date have suggested a functional role for PTPRZ1 in
SCLC cells. As PTPRZ1 has been linked to protein tyro-
sine phosphatase activity, we first assessed the ability of
PTPRZ1 to regulate tyrosine phosphorylation in the re-
sponse to the ligand of PTPRZ1, PTN. PTN binding to
the extracellular portion of PTPRZ1 brings two mole-
cules into close proximity and consequently the phos-
phatase domains dimerize in a head-to-toe arrangement
with the D2 domain of one molecule blocking the active
site (D1) of the second molecule, leading to suppression
of phosphatase activity [31,32]. To identify molecular
targets regulated by PTPRZ1 in response to PTN, we
assessed tyrosine-phosphorylated proteins using an anti-
phosphotyrosine antibody by WB. Interestingly, we
detected two specific bands that migrated just above and
below 15 kDa within 30–60 min after PTN addition to
SCLC cells (Figure 4A). Although it appears that those
bands could be detected at low levels in the absence of
PTN, the addition of PTN significantly induced phos-
phorylation that peaked at 1 h. Since calmodulins (CaM)
are highly abundant, 17 kDa proteins in the mammalian
brain, nervous and endocrine systems and directly inter-
act with the intracellular domain of PTPR members
[33,34], we hypothesized that PTPRZ1 may normally
dephosphorylate the phosphorylated tyrosine residue at
Tyr99 of CaM. To test this idea, we assessed the phos-
phorylation of CaM using an anti- phospho-Tyr99-CaM
(p-CaM) Ab and determined that the upper band could
indeed be identified as CaM (Figure 4B).
PTPRZ1 is required for the tyrosine phosphorylation of
CaM induced by PTN
To verify that the addition of PTN facilitated CaM phos-
phorylation specifically through its receptor PTPRZ1, we
utilized the H69 and H1930 cell lines in which shZ1 was
used to knock down PTPRZ1 expression. Although PTN
induced tyrosine phosphorylation of CaM in H69 cells
that expressed the control shLUC, the ablation of
Figure 3 PTPRZ1 expression was downregulated by shRNA in SCLC cell lines. A, shRNA targeting PTPRZ1 (shZ1) successfully knock-downed
PTPRZ1 mRNA by up to 75% in the SCLC cell lines, H69 and H1930, as compared to negative control construct expressing shLUC. White bars =
shLUC, dotted bars = shZ1#1, gray bars = shZ1#2, black bars = shZ1#3. Error bars represent SD. Asterisk denotes P < 0.05 using Student’s t test,
while NS denotes non-significant change. B, PTPRZ1 downregulation in H69 and H1930 was confirmed by Western blot, using β-tubulin as
control for protein levels. C, FACS analysis of surface PTPRZ1 protein expression on H69 and H1930 cells, with shZ1 down-regulating PTPRZ1
expression levels.
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ylation in cells that expressed either of the two shZ1
constructs (Figure 4C). We confirm that PTPRZ1 was
indispensable for the PTN-induced p-CaM in H1930
cells (Figure 4D).
As the serum levels of PTN were elevated in most
SCLC patients in comparison to healthy controls [12],
we thought PTPRZ1 expression might be correlate with
the expression of phosphorylated CaM. To assess
whether PTPRZ1-CaM regulation also occurred in vivo
in human tissue, we stained for CaM and p-CaM. Indeed
we found that the expression of PTPRZ1 and p-CaM
was statistically correlated in human lung NET tissues
(Figure 4E). These data thus demonstrate that ablationof PTPRZ1 prevents PTN-stimulated tyrosine phosphor-
ylation of CaM in PTN-stimulated SCLC cells; the data
indicate that endogenous PTPRZ1 is required for PTN-
stimulating tyrosine phosphorylation of CaM in SCLC
cells.
PTPRZ1 regulates tumor progression of SCLC in xenograft
model
Many PTPRs play an important role as tumor suppres-
sors [9], yet PTPRZ1 has a role in cell migration and
tumor growth in vivo in glioma studies [20]. To deter-
mine whether overexpressed PTPRZ1 acts as a tumor
suppressor or tumor promoter in human NETs, we used
the severe combined immunodeficiency (SCID) murine
Figure 4 PTPRZ1 regulates tyrosine phosphorylation in SCLC cells. A, Tyrosine phosphorylated proteins in H69 cells were detected by
Western blot with anti-pTyr antibody (4 G10) with β-catenin as loading control on top. B, Tyrosine phosphorylated CaM was detected by Western
blot with anti-phosphorylated CaM, with total CaM on top as loading control in H69 cells. C and D, shZ1s block PTN-stimulated tyrosine
phosphorylation of CaM in H69 (C) and H1930 (D). PTPRZ1 promotes the phosphorylation of calmodulin in response to PTN. E, Correlated
expression of PTPRZ1 and tyrosine phosphphorylated CaM (pCaM) in human lung NET tissues. Representative negative (−) or positive (+) images
were shown. Scale bars were 20 μm (Magnification X40). P < 0.05 was considered statistically significant.
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human SCLC cells. 2 x 106 H69 cells expressing either
shLUC (H69 + shLUC) as a control or shZ1#2 (H69 +
shZ1#2) were subcutaneously transplanted into the
flanks of SCID mice (n = 7) and tumor size was mea-
sured over time. In this mouse model, H69 + shLUC
cells started to grow exponentially at 7 days post-
transplant and progressively form tumor masses for
5 weeks (Figure 5A). In contrast, the H69 + shZ1#2 cells
were impaired for tumor formation until 3 weeks post-
transplant such that tumors were barely recognized
under the skin and were about 3-fold smaller than those
in H69 + shLUC cells (Figure 5A and B). Gross examin-
ation of H69 + shZ1#2 tumors revealed a dramatic loss
of SCLC pathology in the tumor (Figure 5B). To exclude
the possibility of off-target effects of shZ2#2, wesubcutaneously transplanted H69 cells expressing either
shLUC (H69 + shLUC) as a control or shZ1#3 (H69 +
shZ1#3) into the flanks of SCID mice (n = 7) and we
obtained similar results (Figure 5C). In another SCLC
cell line, H1930, the reduction of PTPRZ1 expression
decreased the rate of tumor formation under the skin in
SCID mice as compared to the cells expressing the
shLUC control (Figure 5D). These results provide proof
that PTPRZ1 regulates tumor growth in vivo and has an
oncogenic function in NET progression.
Discussion
Here we demonstrate that PTPRZ1 specifically exists in
human NET tissues and PTPRZ1 has an important
oncogenic role in the tumor progression of SCLC in the
murine xenograft model. We also found that PTPRZ1
Figure 5 PTPRZ1 regulates tumor progression in a SCLC xenograft mouse model. A and B, in vivo growth of SCLC NCI-H69 expressing
shLUC (blue diamonds) and shZ1#2 (red squares) in SCID mice. The loss of PTPRZ1 in cells expressing shZ1#2 inhibited tumor growth as compared
to cells expressing the control shLUC. Tumor size (mm3) over period (A) and gross tumor pathology 5 weeks post-transplant are shown (B). Scale
bar indicates 10 mm. C and D, Deficient in vivo growth of tumors was confirmed using H69 cells expressing shZ1#3 (C) and H1930 cells
expressing shZ1#2. Control SCLC cells with shLUC are shown as blue diamonds while cells with shZ1 are shown as red squares. Error bars are SD.
Asterisk, P < 0.05; double asterisk, P < 0.01; both using Student’s t test.
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sponse to PTN in SCLC cells. Our results indicate that
the putative tumor suppressor family PTPR can support
tumor progression and is required for the tyrosine phos-
phorylation of CaM. This study supports the idea that a
new signaling pathway involving PTPRZ1 could be a
feasible target for treatment of cancers. The combination
of our cellular and xenograft model findings advocates
for the future preclinical testing of antibody therapy or
small molecule inhibitors of PTPRZ1 for the treatment
of NETs and SCLC.
The linkage between oncogenic PTPRZ1 function and
CaM phosphorylation is still unclear. Perez-Pinera and
colleagues demonstrated that phosphorylation of Ana-
plastic lymphoma kinase (ALK) in PTN-stimulated cells
is mediated through the PTN/PTPRZ1 signaling path-
way [35], indicating that ALK might phosphorylate
CaM. Further experiments are needed to address the
possibility of PTN mediating its effects via ALK [35] inSCLC cells, the effects of PTN deletion on tumor
growth, and the mechanism of PTN/PTPRZ1 autocrine
regulation in NET cells. CaM can bind up to four cal-
cium ions, and can undergo post-translational modifica-
tions such as phosphorylation, acetylation, methylation
and proteolytic cleavage, each of which can potentially
modulate its actions [34]. A prior biochemical study
showed that tyrosine phosphorylation increased the as-
sociation of CaM with nitric oxide synthase (NOS) [36].
Because nitric oxide (NO) and NOS are ubiquitous in
malignant tumors and known to exert pro-tumor effects
[37,38], PTPRZ1 may regulate NO production in SCLC
cells by changing the tyrosine phosphorylation status of
CaM. Tumor cell-derived NO promotes tumor progres-
sion by induction of tumor-cell invasion, proliferation
and the expression of angiogenic factors [37,38]. Indeed
a recent research article demonstrated that glioma stem
cell proliferation and tumor growth are promoted by
iNOS [39].
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PTPRZ1 has a huge extracellular domain consisting of a
alpha-carbonic anhydrase domain (CA), chondroitin sul-
fate proteoglycans (CS-PGs), and a fibronectin type-III
domain (FNIII). PTPRZ1 expression is dramatically
induced by hypoxic stress through HIF-2α [19], suggest-
ing that PTPRZ1 may have an important role under hyp-
oxic conditions. Recently, Jeong’s research group
reported that CA was dramatically up-regulated in
human SCLC tissues by proteomic analysis [40]. A pos-
sible speculation is that the CA domain of PTPRZ1
could have an important function for tumor progression
of SCLC and further studies will be required to address
this issue.Conclusions
We found that PTPRZ1 has an important oncogenic role
in tumor progression in the murine xenograft model of
SCLCs. Moreover we demonstrate that the binding of
PTPRZ1 to its ligand PTN inactivates phosphatase activ-
ity, resulting in tyrosine phosphorylation of CaM in
human tumors. These results indicate that a new signal-
ing pathway involving PTPRZ1 could be a feasible target
for treatment of NETs.
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